Sökning: onr:"swepub:oai:DiVA.org:liu-46244" >
A randomized phase ...
-
Glimelius, BengtKarolinska Institutet,Uppsala universitet,Enheten för onkologi,Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden, Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
(författare)
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer
- Artikel/kapitelEngelska2008
Förlag, utgivningsår, omfång ...
-
Elsevier BV,2008
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-46244
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-46244URI
-
https://doi.org/10.1093/annonc/mdm588DOI
-
https://lup.lub.lu.se/record/1204941URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-17421URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:116968774URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background: To compare irinotecan with the Nordic 5-fluorouracil (5-FU) and folinic acid (FA) bolus schedule [irinotecan 180 mg/m2 on day 1, 5-FU 500 mg/m2 and FA 60 mg/m2 on day 1 and 2 (FLIRI)] or the Lv5FU2 schedule [irinotecan 180 mg/m2 on day 1, FA 200 mg/m2, 5-FU bolus 400 mg/m2 and infused 5-FU 600 mg/m2 on day 1 and 2 (Lv5FU2-IRI)] due to uncertainties about how to administrate 5-FU with irinotecan. Patients and methods: Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI. Primary end point was progression-free survival (PFS). Results: Patient characteristics were well balanced. PFS did not differ between groups (median 9 months, P = 0.22). Overall survival (OS) was also similar (median 19 months, P = 0.9). Fewer objective responses were seen in the FLIRI group (35% versus 49%, P = 0.001) but the metastatic resection rate did not differ (4% versus 6%, P = 0.3). Grade 3/4 neutropenia (11% versus 5%, P = 0.01) and grade 2 alopecia (18% versus 9%, P = 0.002) were more common in the FLIRI group. The 60-day mortality was 2.4% versus 2.1%. Conclusions: Irinotecan with the bolus Nordic schedule (FLIRI) is a convenient treatment with PFS and OS comparable to irinotecan with the Lv5FU2 schedule. Neutropenia and alopecia are more prevalent, but both regimens are equally well tolerated. © The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Sorbye, H.Sørbye, H., Department of Oncology, Haukeland University Hospital, Bergen, Norway
(författare)
-
Balteskard, L.Department of Oncology, University Hospital, Tromsö, Norway
(författare)
-
Bystrom, P.Byström, P., Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden
(författare)
-
Pfeiffer, P.Department of Oncology, University Hospital, Odense, Denmark
(författare)
-
Tveit, K.Department of Oncology, Ullevål University Hospital, Oslo, Norway
(författare)
-
Heikkila, R.Heikkilä, R., Department of Hemato-Oncology, Stavanger University Hospital, Stavanger, Norway
(författare)
-
Keldsen, N.Department of Oncology, Central Hospital, Herning, Denmark
(författare)
-
Albertsson, M.Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, University Hospital, Malmö, Sweden(Swepub:lu)onk-mal
(författare)
-
Starkhammar, HansÖstergötlands Läns Landsting,Linköpings universitet,Hälsouniversitetet,Onkologi,Onkologiska kliniken US(Swepub:liu)hanst87
(författare)
-
Garmo, HRegional Oncologic Center, Uppsala, Sweden(Swepub:uu)hga27600
(författare)
-
Berglund, ÅkeUppsala universitet,Enheten för onkologi,Berglund, Å., Department of Oncology, Radiology and Clinical Immunology, Uppsala University Hospital, SE-751 85 Uppsala, Sweden(Swepub:uu)akebergl
(författare)
-
Uppsala universitetEnheten för onkologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Annals of Oncology: Elsevier BV19:5, s. 909-9140923-75341569-8041
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Glimelius, Bengt
-
Sorbye, H.
-
Balteskard, L.
-
Bystrom, P.
-
Pfeiffer, P.
-
Tveit, K.
-
visa fler...
-
Heikkila, R.
-
Keldsen, N.
-
Albertsson, M.
-
Starkhammar, Han ...
-
Garmo, H
-
Berglund, Åke
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Annals of Oncolo ...
- Av lärosätet
-
Linköpings universitet
-
Lunds universitet
-
Uppsala universitet
-
Karolinska Institutet